This week’s China biopharma roundup from PharmaBoardroom content partner Selesta covers Novartis’ USD 5.4bn expansion with Argo in cardiovascular siRNA, Hengrui’s USD 1.1bn out-licensing of its cardiac myosin inhibitor, Novatim’s USD 1.15bn ADC deal with Radiance, Convalife’s Hong Kong IPO filing, and Fosun’s TYK2/JAK1 rights buy. On the clinical side, BioNTech/Duality’s HER2 ADC beats Roche’s Kadcyla in Phase III, Sanofi secures China approval for teplizumab in type 1 diabetes, Hansoh wins first global nod for IgG4-RD, Hengrui files its dual GLP-1/GIP agonist for obesity, and HemaCell advances the world’s first allogeneic megakaryocyte therapy into trials.
